You are here:

Ciclesonide (Alvesco®)


Following a full submission

Ciclesonide (Alvesco) is accepted for restricted use within NHS Scotland for treatment to control persistent asthma in adolescents (aged at least 12 years and <18 years)

It is restricted to asthma patients who require once-daily administration of an inhaled corticosteroid and whose treatment is at step 2 or step 3 of the British Guideline on the Management of Asthma. Alternative inhaled steroids are available at lower cost.

Drug Details

Drug Name: Ciclesonide (Alvesco®)
SMC Drug ID: 249/06
Manufacturer: Altana Pharma Ltd
Indication: Persistent asthma in adolescents aged 12 years and over
BNF Category:
Sub Category: 3.2 Corticosteroids
Submission Type: Full submission
Status: Restricted
Date Advice Published: 12 June 2006